| Therapeutic | Daratumumab |
| Target | ADPRC1/CD38 |
| Heavy Chain | EVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSS |
| Light Chain | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIK |
| 100% seqID Fv Structure | 7dha [Fvs: CB], 7dun [Fvs: HL], 7duo [Fvs: HL] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 7dun [Fvs: HL] |
| 100% seqID Structure | 7duo [Fvs: HL] |
| 100% seqID Structure | 7dha [Fvs: CB] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (Feb '25) | Approved |
| Estimated Status (Feb '25) | Active |
| Recorded Developmental Technology | Medarex HuMAb Mouse |
| INN Year Proposed | 2009 |
| INN Year Recommended | 2010 |
| Companies Involved | Boston Medical Center, Bristol-Myers Squibb, Dana-Farber Cancer Institute, French Innovative Leukemia Organisation, Genentech, Genmab, Janssen Biotech, Janssen Research & Development, M. D. Anderson Cancer Center, Syros Pharmaceuticals |
| Conditions Approved | Multiple myeloma |
| Conditions Active | Amyloid light-chain amyloidosis, Acute myeloid leukaemia, Chronic lymphocytic leukaemia, Diffuse large B cell lymphoma, Follicular lymphoma, Mantle-cell lymphoma, Myelodysplastic syndromes, Precursor B-cell lymphoblastic leukaemia-lymphoma, Precursor T-cell lymphoblastic leukaemia-lymphoma, Prostate cancer, T-cell lymphoma, Waldenstrom's macroglobulinaemia, Solid tumours |
| Conditions Discontinued | Non-small cell lung cancer |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
